abstract: BACKGROUND: Laparoscopic resection has been considered a relative contraindication for T4 @entity4 due to concern over inadequate margins. The objective of this study was to compare planned laparoscopic and open resections of @entity2 with respect to the positive margin rate. METHODS: Data were obtained from the American College of Surgeons National Surgical Quality Improvement Program @entity0 use file to perform a retrospective cohort analysis. The study population consisted of @entity0 that underwent a colorectal resection for a primary T4 lesion during 2011 and 2012. A multiple logistic regression analysis was conducted to determine the adjusted odds ratio (OR) of positive margins based on surgical approach. An inverse probability of treatment weighting (IPTW) analysis was used to account for confounding by indication. A sensitivity analysis including only "as-treated" cases was also performed. RESULTS: The sub-selected population consisted of 455 and 406 @entity0 in the laparoscopic and open group, respectively. In the original cohort, demographic variables were similar. The open group had a higher incidence of comorbidities, @entity1 , and emergency cases. Laparoscopic surgery was found to be no different than open surgery with respect to positive margin status (OR 1.10, p  =  0.54). After IPTW adjustment, surgical approach remained a nonsignificant predictor of positive margins (OR 1.18, p  =  0.31). The "as-treated" analysis also showed that surgical approach had no significant effect on the positive margin rate (OR 1.24, p  =  0.24). CONCLUSIONS: Using this large national surgical database, select @entity0 with @entity2 who underwent planned laparoscopic colorectal resections did not have a significantly higher positive margin rate compared with @entity0 with open operations. Further research is needed to identify the role of laparoscopy in managing T4b lesions before any consensus can be reached regarding its application in locally advanced @entity3 .

title: Laparoscopic versus open surgery for T4 XXXX : evaluation of margin status.

answer: @entity3


abstract: OBJECTIVE: Brivaracetam (BRV) is a new antiepileptic drug candidate rationally designed for high affinity and selectivity for the @entity5 . This study explored anti-ictogenic and antiepileptogenic effects of BRV in @entity0 at different stages of development. METHODS: Using a rapid kindling model in @entity3 , @entity2 , @entity4 , and P60 @entity0 , we studied two doses of BRV: 10 and 100  mg/kg injected intraperitoneally 30  min before afterdischarge assessment. We also assessed blood and brain concentrations of BRV 30  min after the injection. RESULTS: BRV 100  mg/kg significantly increased the afterdischarge threshold (ADT) at all ages, whereas BRV at 10  mg/kg increased ADT in P60, @entity4 , and @entity2 @entity0 . BRV also shortens the afterdischarge duration (ADD), achieving statistical significance with 10 and 100  mg/kg at P60 and with 100  mg/kg at @entity2 . At P60, BRV increases the number of stimulations required to achieve a stage 4-5 @entity1 in a dose-dependent manner. At @entity4 and @entity2 , BRV increased the number of stimulations required to develop a stage 4-5 @entity1 in a dose-dependent manner with almost complete elimination of stage 4-5 @entity1 . In contrast, at @entity3 , BRV had no effect on the number of stage 4-5 @entity1 . An age-related decrease in blood and brain concentrations of BRV was observed 30  min after injection of BRV 10  mg/kg, whereas with 100  mg/kg there were no significant age-correlated differences in brain and serum BRV concentrations. SIGNIFICANCE: BRV exerted dose-dependent anti-ictogenic effects from P60 to @entity3 independent of brain maturation. BRV also exhibited antiepileptogenic effects at P60, whereas this effect need to be further evaluated at @entity4 and @entity2 . We did not observe any effect on epileptogenesis at @entity3 at either dose.

title: Anti-ictogenic and antiepileptogenic properties of brivaracetam in mature and immature XXXX .

answer: @entity0


abstract: BACKGROUND: @entity2 and immune response play a crucial role in @entity1 growth, and the neutrophil to lymphocyte ratio (NLR) may be a simple way to assess the host inflammatory response. The NLR has been shown to be a prognostic indicator in many @entity0 @entity1 ; in early @entity3 , it has been evaluated only in a few studies and its role remains controversial. METHODS: We analyzed data from 503 @entity3 @entity0 . The best cutoff value for NLR was defined by receiver operating characteristic curve analysis. We grouped 276 @entity3 , not receiving adjuvant chemotherapy, into low (<2.36) and high (>2.36) NLR and subjected to further analyses related to disease-free survival (DFS). A propensity score-matched analysis and the inverse probability of treatment weighting (IPTW) were performed to avoid confounding bias. RESULTS: The NLR correlated with @entity1 stage and oncologic outcome. The best NLR cutoff value was identical in the whole cohort and in @entity4 /B @entity0 . Low NLR @entity0 had a significantly better DFS rate than high NLR @entity0 (hazard ratio [HR], 0.27; P = .0001); along with elevated carcinoembryonic antigen levels and Dukes B stage, high NLR was an independent prognostic factor of worse prognosis (HR, 2.86; P = .0033). Even in @entity4 @entity0 , NLR discriminated between relapsing and nonrelapsing @entity0 . Propensity score and IPTW analyses confirmed such results, thus excluding possible misinterpretation. CONCLUSION: Preoperative NLR, an inexpensive and readily available biomarker, can predict @entity1 relapse and should be assessed for implementation of tailored therapy in early stage @entity3 .

title: Neutrophil to lymphocyte ratio is a strong predictor of @entity1 recurrence in early XXXX : A propensity score-matched analysis.

answer: @entity3


abstract: BACKGROUND: @entity2 and immune response play a crucial role in @entity1 growth, and the neutrophil to lymphocyte ratio (NLR) may be a simple way to assess the host inflammatory response. The NLR has been shown to be a prognostic indicator in many @entity0 @entity1 ; in early @entity3 , it has been evaluated only in a few studies and its role remains controversial. METHODS: We analyzed data from 503 @entity3 @entity0 . The best cutoff value for NLR was defined by receiver operating characteristic curve analysis. We grouped 276 @entity3 , not receiving adjuvant chemotherapy, into low (<2.36) and high (>2.36) NLR and subjected to further analyses related to disease-free survival (DFS). A propensity score-matched analysis and the inverse probability of treatment weighting (IPTW) were performed to avoid confounding bias. RESULTS: The NLR correlated with @entity1 stage and oncologic outcome. The best NLR cutoff value was identical in the whole cohort and in @entity4 /B @entity0 . Low NLR @entity0 had a significantly better DFS rate than high NLR @entity0 (hazard ratio [HR], 0.27; P = .0001); along with elevated carcinoembryonic antigen levels and Dukes B stage, high NLR was an independent prognostic factor of worse prognosis (HR, 2.86; P = .0033). Even in @entity4 @entity0 , NLR discriminated between relapsing and nonrelapsing @entity0 . Propensity score and IPTW analyses confirmed such results, thus excluding possible misinterpretation. CONCLUSION: Preoperative NLR, an inexpensive and readily available biomarker, can predict @entity1 relapse and should be assessed for implementation of tailored therapy in early stage @entity3 .

title: Neutrophil to lymphocyte ratio is a strong predictor of XXXX recurrence in early @entity3 : A propensity score-matched analysis.

answer: @entity1


abstract: @entity1 ( @entity1 ) produces multiple alterations in the physiological/biochemical environment of lung cells as well as dysfunction of the lung's surfactant system, which is considered to play a significant role in mediating @entity3 . The present studies were performed using 66 excised @entity0 lungs to evaluate the impact of alterations in ventilation, substrate availability, alveolar @entity2 tension, @entity5 ion and @entity4 concentrations, and temperature and neural denervation on the lamellar body (LB) volume density of type II pneumocytes. Ventilating excised nonperfused @entity0 lungs with room air (0% @entity2 ) for 4 h at 38 degrees C resulted in severe reductions (68-77%) in LB volume density. Supplementing inspired gas with 5% @entity2 prevented LB depletion, while ventilation with 2.5% @entity2 moderated the severity of depletion to 17-27% of control. Ventilation with 10% @entity2 tended to increase LB volume density by increasing the number of LBs per cell, whereas reductions in LB volume density predominantly resulted from a decrease in LB size. The level of ventilation had no significant effect on LB volume density independent of inspired @entity2 concentration. Reducing temperature to 5 degrees C prevented LB depletion. Lung perfusion with autologous whole blood failed to moderate the severity of LB depletion during room air ventilation despite the increased availability of metabolic substrates for cellular metabolism. Adding @entity6 to maintain physiologically normal @entity5 ion concentrations in the perfusing blood had a small effect in ameliorating the severity of LB depletion. These results indicate that alveolar @entity2 tension and @entity4 concentration are major factors regulating the LB content of type II pneumocytes and suggest an important link between the gas exchange and phospholipid metabolic functions of the lung.

title: Factors regulating lamellar body volume density of type II pneumocytes in excised XXXX lungs.

answer: @entity0


abstract: OBJECTIVES: To evaluate the association of prostate biopsy with @entity1 and to investigate whether @entity3 treatment given before prostate biopsy could improve @entity2 after the procedure. METHODS: The study included 88 consecutive @entity0 who underwent transrectal ultrasound-guided prostate biopsy without prior BPH medication and were prospectively randomized. Of these 88 @entity0 , 44 @entity0 underwent prostate biopsy only without @entity3 treatment and served as the control group. The remaining 44 @entity0 were treated with @entity3 (0.2  mg daily) beginning the day before the biopsy procedure for 7  days. The International Prostate Symptom Score (IPSS) was recorded in all @entity0 before the procedure and on postbiopsy day 7. Maximal flow rate (Q max) and postvoid residual urine volume were recorded in all @entity0 before the procedure and on postbiopsy days 1 and 7. RESULTS: No difference was found in baseline characteristics between the two groups. The IPSS (total, storage, and voiding symptom) was not significantly changed after biopsy in both groups. In the control group, the postvoid residual urine volume was increased on postbiopsy days 1 (P  <  0.05) and 7, and the Q max was significantly decreased on postbiopsy day 7 compared with the baseline value (P  <  0.05). In the @entity3 group, Q max was significantly increased on postbiopsy days 1 and 7 (P  <  0.01). The postvoid residual urine volume was not increased on postbiopsy days 1 and 7. Acute urinary retention after the biopsy procedure did not develop in any of the @entity0 (0  %) in the @entity3 group, but it developed in two @entity0 (4.5  %) of the control group. CONCLUSIONS: The results of our study show that prostate biopsy leads to objective @entity1 . Therefore, the use of alpha-1 blocker @entity3 before biopsy in @entity0 without prior BPH medication may decrease this morbidity.

title: The preventive effect of @entity3 on XXXX after prostate biopsy: a prospective, open-label, observational study.

answer: @entity2


abstract: OBJECTIVES: To evaluate the association of prostate biopsy with @entity1 and to investigate whether @entity3 treatment given before prostate biopsy could improve @entity2 after the procedure. METHODS: The study included 88 consecutive @entity0 who underwent transrectal ultrasound-guided prostate biopsy without prior BPH medication and were prospectively randomized. Of these 88 @entity0 , 44 @entity0 underwent prostate biopsy only without @entity3 treatment and served as the control group. The remaining 44 @entity0 were treated with @entity3 (0.2  mg daily) beginning the day before the biopsy procedure for 7  days. The International Prostate Symptom Score (IPSS) was recorded in all @entity0 before the procedure and on postbiopsy day 7. Maximal flow rate (Q max) and postvoid residual urine volume were recorded in all @entity0 before the procedure and on postbiopsy days 1 and 7. RESULTS: No difference was found in baseline characteristics between the two groups. The IPSS (total, storage, and voiding symptom) was not significantly changed after biopsy in both groups. In the control group, the postvoid residual urine volume was increased on postbiopsy days 1 (P  <  0.05) and 7, and the Q max was significantly decreased on postbiopsy day 7 compared with the baseline value (P  <  0.05). In the @entity3 group, Q max was significantly increased on postbiopsy days 1 and 7 (P  <  0.01). The postvoid residual urine volume was not increased on postbiopsy days 1 and 7. Acute urinary retention after the biopsy procedure did not develop in any of the @entity0 (0  %) in the @entity3 group, but it developed in two @entity0 (4.5  %) of the control group. CONCLUSIONS: The results of our study show that prostate biopsy leads to objective @entity1 . Therefore, the use of alpha-1 blocker @entity3 before biopsy in @entity0 without prior BPH medication may decrease this morbidity.

title: The preventive effect of XXXX on @entity2 after prostate biopsy: a prospective, open-label, observational study.

answer: @entity3


abstract: OBJECTIVE: @entity0 safety is critical for @entity1 monitoring units ( @entity3 ). Effective training is important for educating all personnel, including residents and nurses who frequently cover these units. We performed a needs assessment and developed a simulation-based team training curriculum employing actual @entity3 sentinel events to train neurology resident-nurse interprofessional teams to maximize effective responses to high-acuity events. METHODS: A mixed-methods design was used. This included the development of a safe-practice checklist to assess team response to acute events in the @entity3 using expert review with consensus (a modified Delphi process). All nineteen incoming first-year neurology residents and 2 nurses completed a questionnaire assessing baseline knowledge and attitudes regarding @entity2 management prior to and following a team training program employing simulation and postscenario debriefing. Four resident-nurse teams were recorded while participating in two simulated scenarios. Employing retrospective video review, four trained raters used the newly developed safe-practice checklist to assess team performance. We calculated the interobserver reliability of the checklist for consistency among the raters. We attempted to ascertain whether the training led to improvement in performance in the actual @entity3 by comparing 10 videos of resident-nurse team responses to @entity2 4-8months into the academic year preceding the curricular training to 10 that included those who received the training within 4-8months of the captured video. RESULTS: Knowledge in @entity2 management was significantly improved following the program, but confidence in @entity2 management was not. Interrater agreement was moderate to high for consistency of raters for the majority of individual checklist items. We were unable to demonstrate that the training led to sustainable improvement in performance in the actual @entity3 by the method we used. CONCLUSIONS: A simulated team training curriculum using a safe-practice checklist to improve the management of acute events in an @entity3 may be an effective method of training neurology residents. However, translating the results into sustainable benefits and confidence in management in the @entity3 requires further study.

title: Interprofessional simulation to improve safety in the XXXX monitoring unit.

answer: @entity1


abstract: UNASSIGNED: Clinical and preclinical research suggest that activation of the mesolimbic @entity3 (DA) system is involved in mediating the rewarding actions of drugs of abuse, as well as promoting drug-seeking behavior. Inhibition of @entity7 receptors in the nucleus accumbens (Acb) can reduce @entity4 ( @entity1 )-seeking behavior of non-selective @entity0 triggered by environmental context. However, to date, there has been no research on the effects of D1 receptor agents on @entity1 - seeking behavior of high @entity2 -preferring ( @entity5 following prolonged abstinence. The objective of the present study was to examine the effects of microinjecting the D1 antagonist @entity6 or the D1 agonist @entity8 into the Acb shell or Acb core on spontaneous recovery of @entity1 -seeking behavior. After 10weeks of concurrent access to @entity1 and water, @entity5 underwent seven extinction sessions ( @entity1 and water withheld), followed by 2weeks in their home cages without access to @entity1 or operant sessions. In the 2nd week of the home cage phase, @entity0 were bilaterally implanted with guide cannula aimed at the Acb shell or Acb core; @entity0 were allowed 7days to recover before @entity1 -seeking was assessed by the Pavlovian Spontaneous Recovery (PSR) model. Administration of @entity6 (1 g/side) into the Acb shell inhibited responding on the @entity1 lever, whereas administration of @entity8 (0.125 g/side) increased responding on the @entity1 lever. Microinfusion of D1 receptor agents into the Acb core did not alter responding on the @entity1 lever. Responses on the water lever were not altered by any of the treatments. The results suggest that activation of D1 receptors within the Acb shell, but not Acb core, are involved in mediating PSR of @entity1 -seeking behavior of @entity5 .

title: D1 receptors in the nucleus accumbens-shell, but not the core, are involved in mediating @entity4 -seeking behavior of XXXX -preferring ( @entity5 .

answer: @entity2


abstract: UNASSIGNED: Clinical and preclinical research suggest that activation of the mesolimbic @entity3 (DA) system is involved in mediating the rewarding actions of drugs of abuse, as well as promoting drug-seeking behavior. Inhibition of @entity7 receptors in the nucleus accumbens (Acb) can reduce @entity4 ( @entity1 )-seeking behavior of non-selective @entity0 triggered by environmental context. However, to date, there has been no research on the effects of D1 receptor agents on @entity1 - seeking behavior of high @entity2 -preferring ( @entity5 following prolonged abstinence. The objective of the present study was to examine the effects of microinjecting the D1 antagonist @entity6 or the D1 agonist @entity8 into the Acb shell or Acb core on spontaneous recovery of @entity1 -seeking behavior. After 10weeks of concurrent access to @entity1 and water, @entity5 underwent seven extinction sessions ( @entity1 and water withheld), followed by 2weeks in their home cages without access to @entity1 or operant sessions. In the 2nd week of the home cage phase, @entity0 were bilaterally implanted with guide cannula aimed at the Acb shell or Acb core; @entity0 were allowed 7days to recover before @entity1 -seeking was assessed by the Pavlovian Spontaneous Recovery (PSR) model. Administration of @entity6 (1 g/side) into the Acb shell inhibited responding on the @entity1 lever, whereas administration of @entity8 (0.125 g/side) increased responding on the @entity1 lever. Microinfusion of D1 receptor agents into the Acb core did not alter responding on the @entity1 lever. Responses on the water lever were not altered by any of the treatments. The results suggest that activation of D1 receptors within the Acb shell, but not Acb core, are involved in mediating PSR of @entity1 -seeking behavior of @entity5 .

title: D1 receptors in the nucleus accumbens-shell, but not the core, are involved in mediating @entity4 -seeking behavior of @entity2 -preferring ( XXXX .

answer: @entity5


abstract: UNASSIGNED: Clinical and preclinical research suggest that activation of the mesolimbic @entity3 (DA) system is involved in mediating the rewarding actions of drugs of abuse, as well as promoting drug-seeking behavior. Inhibition of @entity7 receptors in the nucleus accumbens (Acb) can reduce @entity4 ( @entity1 )-seeking behavior of non-selective @entity0 triggered by environmental context. However, to date, there has been no research on the effects of D1 receptor agents on @entity1 - seeking behavior of high @entity2 -preferring ( @entity5 following prolonged abstinence. The objective of the present study was to examine the effects of microinjecting the D1 antagonist @entity6 or the D1 agonist @entity8 into the Acb shell or Acb core on spontaneous recovery of @entity1 -seeking behavior. After 10weeks of concurrent access to @entity1 and water, @entity5 underwent seven extinction sessions ( @entity1 and water withheld), followed by 2weeks in their home cages without access to @entity1 or operant sessions. In the 2nd week of the home cage phase, @entity0 were bilaterally implanted with guide cannula aimed at the Acb shell or Acb core; @entity0 were allowed 7days to recover before @entity1 -seeking was assessed by the Pavlovian Spontaneous Recovery (PSR) model. Administration of @entity6 (1 g/side) into the Acb shell inhibited responding on the @entity1 lever, whereas administration of @entity8 (0.125 g/side) increased responding on the @entity1 lever. Microinfusion of D1 receptor agents into the Acb core did not alter responding on the @entity1 lever. Responses on the water lever were not altered by any of the treatments. The results suggest that activation of D1 receptors within the Acb shell, but not Acb core, are involved in mediating PSR of @entity1 -seeking behavior of @entity5 .

title: D1 receptors in the nucleus accumbens-shell, but not the core, are involved in mediating XXXX -seeking behavior of @entity2 -preferring ( @entity5 .

answer: @entity4


abstract: CONCLUSION: Grade >=  3 @entity1 / @entity6 and inability to feed orally were problematic for @entity0 undergoing cetuximab-based bioradiotherapy (BRT) as well as @entity4 -based chemoradiotherapy (CRT). Severe @entity1 / @entity6 and @entity7 should be addressed carefully in @entity0 undergoing cetuximab-based BRT as well. OBJECTIVES: The efficacy of cetuximab-based BRT in locally advanced head and neck @entity5 has been established. However, the safety of cetuximab-based BRT in comparison with @entity4 -based CRT is currently under investigation. METHOD: This study retrospectively analyzed 14 @entity0 undergoing cetuximab-based BRT and 29 @entity0 undergoing @entity4 -based CRT to compare the incidence of acute @entity2 . In the BRT group, an initial cetuximab loading dose of 400 mg/m(2) was delivered 1 week before the start of radiotherapy. Seven weekly infusions of 250 mg/m(2) of cetuximab followed during the definitive radiotherapy. In the CRT group, @entity3 was administered at a dose of 40 mg/m(2) weekly during the definitive radiotherapy. RESULTS: The BRT group had a higher incidence of Grade >=  3 @entity7 than did the CRT group (43% vs 3%, respectively, p < 0.01). The incidence rate of Grade >=  3 @entity1 / @entity6 was 64.3% and 41.4% in the BRT and CRT group, respectively (p = 0.1484), while the incidence rate of the inability to feed orally was 38.5% and 55.2%, respectively (p = 0.2053).

title: Comparison of acute @entity2 associated with cetuximab-based bioradiotherapy and @entity4 -based chemoradiotherapy for head and neck XXXX : A single-institution retrospective study in Japan.

answer: @entity5


abstract: CONCLUSION: Grade >=  3 @entity1 / @entity6 and inability to feed orally were problematic for @entity0 undergoing cetuximab-based bioradiotherapy (BRT) as well as @entity4 -based chemoradiotherapy (CRT). Severe @entity1 / @entity6 and @entity7 should be addressed carefully in @entity0 undergoing cetuximab-based BRT as well. OBJECTIVES: The efficacy of cetuximab-based BRT in locally advanced head and neck @entity5 has been established. However, the safety of cetuximab-based BRT in comparison with @entity4 -based CRT is currently under investigation. METHOD: This study retrospectively analyzed 14 @entity0 undergoing cetuximab-based BRT and 29 @entity0 undergoing @entity4 -based CRT to compare the incidence of acute @entity2 . In the BRT group, an initial cetuximab loading dose of 400 mg/m(2) was delivered 1 week before the start of radiotherapy. Seven weekly infusions of 250 mg/m(2) of cetuximab followed during the definitive radiotherapy. In the CRT group, @entity3 was administered at a dose of 40 mg/m(2) weekly during the definitive radiotherapy. RESULTS: The BRT group had a higher incidence of Grade >=  3 @entity7 than did the CRT group (43% vs 3%, respectively, p < 0.01). The incidence rate of Grade >=  3 @entity1 / @entity6 was 64.3% and 41.4% in the BRT and CRT group, respectively (p = 0.1484), while the incidence rate of the inability to feed orally was 38.5% and 55.2%, respectively (p = 0.2053).

title: Comparison of acute XXXX associated with cetuximab-based bioradiotherapy and @entity4 -based chemoradiotherapy for head and neck @entity5 : A single-institution retrospective study in Japan.

answer: @entity2


abstract: CONCLUSION: Grade >=  3 @entity1 / @entity6 and inability to feed orally were problematic for @entity0 undergoing cetuximab-based bioradiotherapy (BRT) as well as @entity4 -based chemoradiotherapy (CRT). Severe @entity1 / @entity6 and @entity7 should be addressed carefully in @entity0 undergoing cetuximab-based BRT as well. OBJECTIVES: The efficacy of cetuximab-based BRT in locally advanced head and neck @entity5 has been established. However, the safety of cetuximab-based BRT in comparison with @entity4 -based CRT is currently under investigation. METHOD: This study retrospectively analyzed 14 @entity0 undergoing cetuximab-based BRT and 29 @entity0 undergoing @entity4 -based CRT to compare the incidence of acute @entity2 . In the BRT group, an initial cetuximab loading dose of 400 mg/m(2) was delivered 1 week before the start of radiotherapy. Seven weekly infusions of 250 mg/m(2) of cetuximab followed during the definitive radiotherapy. In the CRT group, @entity3 was administered at a dose of 40 mg/m(2) weekly during the definitive radiotherapy. RESULTS: The BRT group had a higher incidence of Grade >=  3 @entity7 than did the CRT group (43% vs 3%, respectively, p < 0.01). The incidence rate of Grade >=  3 @entity1 / @entity6 was 64.3% and 41.4% in the BRT and CRT group, respectively (p = 0.1484), while the incidence rate of the inability to feed orally was 38.5% and 55.2%, respectively (p = 0.2053).

title: Comparison of acute @entity2 associated with cetuximab-based bioradiotherapy and XXXX -based chemoradiotherapy for head and neck @entity5 : A single-institution retrospective study in Japan.

answer: @entity4


abstract: UNASSIGNED: The @entity3 ( @entity3 ) from resting-state functional MRI (rs-fMRI) signals can be used to detect intrinsic spontaneous brain activity and provide valuable insights into the pathomechanism of @entity2 . In this study, we recruited 56 @entity0 who had been diagnosed as having mild to severe @entity4 . According to the neuropsychological tests, they were subdivided into a @entity4 with @entity1 group (n=28) and a @entity4 without @entity1 group (n=28). 28 volunteers were included as normal controls. We found that the three groups showed significant differences in @entity3 in the brain regions of the right inferior occipital gyrus (IOG_R), left middle temporal gyrus (MTG_L), left precuneus (Pcu_L), right superior frontal gyrus (SFG_R) and right superior occipital gyrus (SOG_R). Compared with normal controls, the @entity4 without @entity1 group exhibited significantly increased @entity3 in the IOG_R, Pcu_L, SFG_R and SOG_R. While compared with @entity4 without @entity1 group, the @entity4 with @entity1 group showed significantly decreased @entity3 in IOG_R, MTG_L, Pcu_L and SOG_R. A close negative correlation was found between the @entity3 values of the MTG_L and the Montreal Cognitive Assessment (MoCA) scores. Our data demonstrate that white matter integrity and @entity1 are associated with different amplitude fluctuations of rs-fMRI signals. @entity4 is related to @entity3 increases in IOG_R, Pcu_L, SFG_Orb_R and SOG_R. @entity3 in MTG_L is characteristic of @entity1 and may aid in its early detection.

title: Abnormal intrinsic brain activity patterns in XXXX with and without @entity1 .

answer: @entity4


abstract: UNASSIGNED: The @entity3 ( @entity3 ) from resting-state functional MRI (rs-fMRI) signals can be used to detect intrinsic spontaneous brain activity and provide valuable insights into the pathomechanism of @entity2 . In this study, we recruited 56 @entity0 who had been diagnosed as having mild to severe @entity4 . According to the neuropsychological tests, they were subdivided into a @entity4 with @entity1 group (n=28) and a @entity4 without @entity1 group (n=28). 28 volunteers were included as normal controls. We found that the three groups showed significant differences in @entity3 in the brain regions of the right inferior occipital gyrus (IOG_R), left middle temporal gyrus (MTG_L), left precuneus (Pcu_L), right superior frontal gyrus (SFG_R) and right superior occipital gyrus (SOG_R). Compared with normal controls, the @entity4 without @entity1 group exhibited significantly increased @entity3 in the IOG_R, Pcu_L, SFG_R and SOG_R. While compared with @entity4 without @entity1 group, the @entity4 with @entity1 group showed significantly decreased @entity3 in IOG_R, MTG_L, Pcu_L and SOG_R. A close negative correlation was found between the @entity3 values of the MTG_L and the Montreal Cognitive Assessment (MoCA) scores. Our data demonstrate that white matter integrity and @entity1 are associated with different amplitude fluctuations of rs-fMRI signals. @entity4 is related to @entity3 increases in IOG_R, Pcu_L, SFG_Orb_R and SOG_R. @entity3 in MTG_L is characteristic of @entity1 and may aid in its early detection.

title: Abnormal intrinsic brain activity patterns in @entity4 with and without XXXX .

answer: @entity1


abstract: BACKGROUND: Using positron emission tomography (PET) it is possible to estimate endogenous dopamine (DA) occupying D2/3 receptors (D2/3R) in the living @entity0 brain. @entity0 with @entity1 ( @entity1 ) (previously medicated and na  ve) have increased endogenous DA occupying D2/3R in the caudate. It is unknown whether currently medicated @entity0 demonstrate increased DA levels at D2/3R. Moreover, DA levels have not been estimated in @entity1 using agonist radiotracers, which may offer a more sensitive quantification over antagonists. METHODS: Using the agonist radiotracer [(11)C]-(+)-PHNO, DA levels were estimated at D2/3R (  BPND) in three @entity0 with @entity1 (male, mean age=30  16). @entity0 were currently being treated long-term with Olanzapine (147  88nmol/L). Results were compared to ten healthy controls (HCs). RESULTS: Medicated @entity0 with @entity1 had greater   BPND in the left caudate (U=2, Z=-2.20, p=.03) and right putamen (U=2, Z=-2.20, p=.03). No differences were observed in the ventral striatum or globus pallidus. CONCLUSIONS: It is possible to estimate endogenous DA at D2/3R in @entity1 @entity0 currently taking antipsychotics. Despite medication, @entity0 continue to have increased endogenous DA at D2/3R. This lends more biological support to the clinical observation that relapses in symptoms can occur in the face of complete antipsychotic discontinuation. Future studies with larger samples are warranted.

title: Examining endogenous dopamine in treated XXXX using [(11)C]-(+)-PHNO positron emission tomography: A pilot study.

answer: @entity1


abstract: BACKGROUND: @entity3 following @entity1 refers to impairments that affect the comprehension and expression of spoken and/or written language, and co-occurring @entity2 are common. In this paper we focus on short-term and working @entity4 that impact on the ability to retain and manipulate auditory-verbal information. Evidence from diverse paradigms (large group studies, case studies) report close links between short-term/working memory and language functioning in @entity3 . This evidence leads to the hypothesis that treating such @entity4 would improve language functioning. This link has only recently been acknowledged in @entity3 treatment but has not been embraced widely by clinicians. AIMS: To examine the association between language, and short-term and working @entity4 in @entity3 . To describe practical ways of assessing short-term and working memory functioning that could be used in clinical practice. To discuss and critically appraise treatments of short-term and working memory reported in the literature. METHODS _ PROCEDURES: Taking a translational research approach, this paper provides clinicians with current evidence from the literature and practical information on how to assess and treat short-term and working @entity4 in @entity0 with @entity3 . Published treatments of short-term and/or working memory in post- @entity1 are discussed through a narrative review. MAIN CONTRIBUTIONS: This paper provides the following. A theoretical rationale for adopting short-term and working memory treatments in @entity3 . It highlights issues in differentially diagnosing between short-term, working @entity4 and other @entity2 , e.g. apraxia of speech. It describes short-term and working memory assessments with practical considerations for use with @entity0 with @entity3 . It also offers a description of published treatments in terms of @entity0 , treatments and outcomes. Finally, it critically appraises the current evidence base relating to the treatment of short-term and working memory treatments. CONCLUSIONS: The links between short-term/working memory functioning and language in @entity3 are generally acknowledged. These strongly indicate the need to incorporate assessment of short-term/working memory functioning for @entity0 with @entity3 . While the supportive evidence for treatment is growing and appears to highlight the benefits of including short-term/working memory in @entity3 treatment, the quality of the evidence in its current state is poor. However, because of the clinical needs of @entity0 with @entity3 and the prevalence of short-term/working @entity4 , incorporating related treatments through practice-based evidence is advocated.

title: Assessment and treatment of short-term and working XXXX in @entity1 : a practical tutorial.

answer: @entity4


abstract: BACKGROUND: @entity3 following @entity1 refers to impairments that affect the comprehension and expression of spoken and/or written language, and co-occurring @entity2 are common. In this paper we focus on short-term and working @entity4 that impact on the ability to retain and manipulate auditory-verbal information. Evidence from diverse paradigms (large group studies, case studies) report close links between short-term/working memory and language functioning in @entity3 . This evidence leads to the hypothesis that treating such @entity4 would improve language functioning. This link has only recently been acknowledged in @entity3 treatment but has not been embraced widely by clinicians. AIMS: To examine the association between language, and short-term and working @entity4 in @entity3 . To describe practical ways of assessing short-term and working memory functioning that could be used in clinical practice. To discuss and critically appraise treatments of short-term and working memory reported in the literature. METHODS _ PROCEDURES: Taking a translational research approach, this paper provides clinicians with current evidence from the literature and practical information on how to assess and treat short-term and working @entity4 in @entity0 with @entity3 . Published treatments of short-term and/or working memory in post- @entity1 are discussed through a narrative review. MAIN CONTRIBUTIONS: This paper provides the following. A theoretical rationale for adopting short-term and working memory treatments in @entity3 . It highlights issues in differentially diagnosing between short-term, working @entity4 and other @entity2 , e.g. apraxia of speech. It describes short-term and working memory assessments with practical considerations for use with @entity0 with @entity3 . It also offers a description of published treatments in terms of @entity0 , treatments and outcomes. Finally, it critically appraises the current evidence base relating to the treatment of short-term and working memory treatments. CONCLUSIONS: The links between short-term/working memory functioning and language in @entity3 are generally acknowledged. These strongly indicate the need to incorporate assessment of short-term/working memory functioning for @entity0 with @entity3 . While the supportive evidence for treatment is growing and appears to highlight the benefits of including short-term/working memory in @entity3 treatment, the quality of the evidence in its current state is poor. However, because of the clinical needs of @entity0 with @entity3 and the prevalence of short-term/working @entity4 , incorporating related treatments through practice-based evidence is advocated.

title: Assessment and treatment of short-term and working @entity4 in XXXX : a practical tutorial.

answer: @entity1


abstract: UNASSIGNED: @entity0 ( @entity0 ) are a heterogeneous group of @entity0 that are often associated with adverse pathological characteristics, poorer clinical outcomes and lack of targeted therapeutic options. Epithelial-mesenchymal transition, which plays a crucial @entity2 development and progression, is characterised by a transition from epithelial to mesenchymal phenotype and loss of proteins involved in maintaining cell junctions. We aimed to correlate protein expression of @entity4 , @entity5 and @entity3 ( @entity3 ) with clinicopathological parameters and survivals of a series of @entity1 with TNBC. The study cohort comprised 767 @entity0 diagnosed at the Department of Pathology, Singapore General Hospital from 1994 to 2012. Immunohistochemistry was performed on sections cut from tissue microarrays using the polymeric method. Staining intensity and percentage of positive @entity2 cells were evaluated and correlated with clinicopathological findings and clinical outcomes. Loss of @entity4 expression, @entity5 positivity, cytoplasmic and nuclear expression of @entity3 were observed in 265 (35.2  %), 241 (32.0  %), 272 (36.2  %) and 262 (34.8  %) @entity2 , respectively. Histological grade significantly correlated with  @entity5 positivity (P < 0.001) and loss of membranous @entity4 expression (P  =  0.003). Nuclear expression of @entity3 was inversely correlated with histological grade (P  =  0.010). Median follow-up was 73  months, with a maximum of 236  months. Despite a graphical curve for earlier recurrence in @entity1 with @entity2 harbouring a combinational phenotype of loss of membranous @entity4 and positive @entity5 expression, there was no statistical significance. Similarly for @entity1 with @entity2 expressing cytoplasmic @entity3 , graphical representation showed poorer metastasis-free survival but without statistical significance. Loss of membranous @entity4 and positive @entity5 expression are significantly associated with high-grade @entity0 . More work is needed to improve understanding of the role of @entity3 in TNBC.

title: Role of epithelial-mesenchymal transition markers in triple-negative XXXX .

answer: @entity0


abstract: UNASSIGNED: There is a significant learning curve for endoscopic submucosal dissection of @entity3 that has not been fully characterized. This retrospective study included 33 consecutive superficial @entity3 for analysis of the learning curve for esophageal endoscopic submucosal dissection based on a single, novice endoscopist's experience. The study was divided into three periods (T1, T2, and T3) of 10 endoscopic submucosal dissection procedures in chronological order, with 13 procedures in the last period. @entity0 factors (age, sex, coexistent esophageal varices, or @entity2 ) and @entity1 factors (location at upper esophagus, involving >3/4 esophageal circumference) for endoscopic submucosal dissection were not statistically different between the periods. The mean procedure time was 74.6   min/cm(2) , 23.4   min/cm(2) , and 10.5   min/cm(2) for T1, T2, and T3, respectively. The procedure time decreased over time (P = 0.02) and post hoc test revealed significant difference was only between T3 and T1 (P = 0.019). The en bloc resection rate was 50%, 100%, and 92.3% for T1, T2, and T3, respectively (P for trend = 0.015). R0 resection rate was 40%, 100%, and 84.6% for T1, T2, and T3, respectively (P for trend = 0.023). Two @entity0 had complications: each one @entity0 in T1 and T3 period experienced major @entity4 during the procedure (P for trend = 0.875). None of the @entity0 had esophageal perforation. The results of the study concluded that at least 30 cases of endoscopic submucosal dissection of @entity3 are needed for a novice endoscopist to gain early proficiency in this technique.

title: Learning curve for endoscopic submucosal dissection of XXXX .

answer: @entity3


abstract: This study determined the contribution of extracellular matrix (ECM) remodeling to the protective adaptation of @entity0 skeletal muscle known as the repeated-bout effect (RBE). Muscle biopsies were obtained 3 hours, 2 days, and 27 days following an initial bout (B1) of lengthening contractions (LCs) and 2 days following a repeated bout (B2) in 2 separate studies. Biopsies from the nonexercised legs served as controls. In the first study, global transcriptomic analysis indicated widespread changes in ECM structural, deadhesive, and signaling transcripts, 3 hours following LC. To determine if ECM remodeling is involved in the RBE, we conducted a second study by use of a repeated-bout paradigm. TNC immunoreactivity increased 10.8-fold following B1, was attenuated following B2, and positively correlated with LC-induced strength loss (r(2) = 0.45; P = 0.009). Expression of collagen I, III, and IV ( @entity4 , @entity1 , @entity3 ) transcripts was unchanged early but increased 5.7    2.5-, 3.2    0.9-, and 2.1    0.4-fold (P < 0.05), respectively, 27 days post-B1 and were unaffected by B2. Likewise, @entity2 signaling demonstrated a delayed response following LC. Satellite cell content increased 80% (P < 0.05) 2 days post-B1 (P < 0.05), remained elevated 27 days post-B1, and was unaffected by B2. Collectively, the data suggest sequential ECM remodeling characterized by early deadhesion and delayed reconstructive activity that appear to contribute to the RBE.

title: Extracellular matrix remodeling and its contribution to protective adaptation following lengthening contractions in XXXX muscle.

answer: @entity0


abstract: BACKGROUND: Over one million @entity0 undergo prostate biopsies annually in the United States, a majority of whom due to elevated serum PSA. More than half of the biopsies turn out to be negative for @entity2 (CaP). The limitations of both the PSA test and the biopsy procedure have led to the development for more precise CaP detection assays in urine (e.g., @entity5 , @entity3 -ERG) or blood (e.g., PHI, 4K). Here, we describe the development and evaluation of the Urine CaP Marker Panel (UCMP) assay for sensitive and reproducible detection of CaP cells in post-digital rectal examination (post-DRE) urine. METHODS: The cellular content of the post-DRE urine was captured on a translucent filter membrane, which is placed on Cytoclear slides for direct evaluation by microscopy and immuno-cytochemistry (ICC). Cells captured on the membrane were assayed for PSA and @entity6 expression to identify prostate epithelial cells, and for ERG and @entity4 to identify @entity2 cells. Immunostained cells were analyzed for quantitative and qualitative features and correlated with biopsy positive and negative status for @entity1 . RESULTS: The assay was optimized for single cell capture sensitivity and downstream evaluations by spiking a known number of cells from established CaP cell lines, LNCaP and VCaP, into pre-cleared control urine. The cells captured from the post-DRE urine of subjects, obtained prior to biopsy procedure, were co-stained for ERG, @entity4 (CaP specific), and @entity6 or PSA (prostate epithelium specific) rendering a whole cell based analysis and characterization. A feasibility cohort of 63 post-DRE urine specimens was assessed. Comparison of the UCMP results with blinded biopsy results showed an assay sensitivity of 64% (16 of 25) and a specificity of 68.8% (22 of 32) for CaP detection by biopsy. CONCLUSIONS: This pilot study assessing a minimally invasive CaP detection assay with single cell sensitivity cell-capture and characterization from the post-DRE urine holds promise for further development of this novel assay platform. Prostate 75: 969-975, 2015.    2015 The Authors. The Prostate, published by Wiley Periodicals, Inc.

title: XXXX marker panel with single cell sensitivity in urine.

answer: @entity2


abstract: BACKGROUND AND OBJECTIVES: @entity0 sensitivity is associated with smoking processes and poorer clinical outcomes. Yet, the specific mechanisms underlying this association are unclear. Smoking-specific avoidance and inflexibility ( @entity3 ) is a construct implicated in multiple manifestations of mood regulation that may underlie smoking severity. The current study examined whether @entity3 accounted for (ie, statistically mediated) the relationship between @entity0 sensitivity and multiple indices of smoking severity. METHODS: Baseline self-report data were collected among treatment-seeking smokers (N   =   396; 48% female; Mage    =   37.8 years) taking part in a larger intervention study. Gender, smoking-related medical history, @entity4 I diagnoses, hazardous @entity1 use, substance abuse/dependence, and negative affectivity were statistically controlled in analyses. RESULTS: @entity0 sensitivity was indirectly related to all smoking severity variables, with the exception of @entity2 dependence, through its relation with @entity3 . DISCUSSION AND CONCLUSIONS: These findings provide initial evidence suggesting @entity3 may be an important construct in better understanding @entity0 sensitivity-smoking relations. SCIENTIFIC SIGNIFICANCE: Results suggest the importance of @entity3 as a malleable target for smoking cessation intervention. (Am J Addict 2015;9999:1-8).

title: Examination of smoking inflexibility as a mechanism linking XXXX sensitivity and severity of smoking behavior.

answer: @entity0


abstract: UNASSIGNED: Cells in our body are constantly exposed to various stresses and threats to their genomic integrity. The @entity0 suppressor protein @entity2 plays a critical role in successful defense against these threats by inducing apoptotic cell death or cell cycle arrest. In unstressed conditions, @entity2 levels and activity must be kept low to prevent lethal activation of apoptotic and senescence pathways. However, upon DNA damage or other stressors, @entity2 is released from its inhibitory state to induce an array of apoptosis and cell cycle genes. Conversely, inactivation of @entity2 could promote unrestrained @entity0 proliferation and failure to appropriately undergo apoptotic cell death, which could, in turn, lead to @entity1 . The ubiquitin E3 ligase @entity3 is the most critical inhibitor of @entity2 that determines the cellular response to various @entity2 -activating agents, including DNA damage. @entity3 activity is controlled by post-translational modifications, especially phosphorylation. However, accumulating evidence suggests that @entity3 is also regulated at the level of protein stability, which is controlled by the ubiquitin-proteasome pathway. Here, we discuss how @entity3 can be regulated in response to DNA damage with particular focus on the regulation of @entity3 protein stability. This article is protected by copyright. All rights reserved.

title: Regulation of XXXX stability as a consequence of DNA damage.

answer: @entity3


abstract: UNASSIGNED: In @entity0 undergoing coronary artery surgery, improvements in clinical outcomes currently rely on continued refinements of the surgical technique and modulation of adjuvant pharmacotherapy. Despite medical and technological advances, negligible rate of @entity4 and @entity1 events still persist necessitating further improvements in @entity0 management. Platelet function testing (PFT) might play an important role in meticulous balancing between the risk of @entity4 and @entity5 events. A suitable balance can be achieved by implementing a personalized, PFT based approach in antiplatelet therapy (APT) administration/discontinuation management. Despite emerging evidence on the widespread variability in platelet inhibitory response to APT, numerous PFT devices and heterogeneity in reporting study results hamper pooling of the evidence which in turn results with a lack of consensus in "on treatment" platelet reactivity associated with @entity1 and @entity4 events in perioperative phase. The literature on multiple electrode aggregometry (Multiplate(  ); Roche Diagnostics, Mannheim, Germany) in @entity3 @entity0 was reviewed systematically. Based on the evidence evaluating the relationship between "drug specific" PFT and @entity4 or adverse @entity1 events, we sought to define therapeutic window for the most commonly administered antiplatelet drugs such as @entity2 (ASPI test) and @entity6 receptor blockers ( @entity6 test). Preoperatively, APT administration was primarily focused to avoid @entity4 complications. ASPI test value of 20 AUC and @entity6 test value of <73 AUC were set as cut-off values that delineate @entity4 tendency. Postoperatively, "therapeutic window" was set to avoid both @entity4 and adverse @entity1 events. Therapeutic ranges were as follows: 20 AUC  <  ASPItest   <=  30 AUC and 19AUC  <  @entity6   <=  46AUC, respectively. This is the first attempt to define PFT based "therapeutic window" according to, perioperative APT administration/discontinuation management would be targeted. It seems that the "one-size-fits-all" concept of perioperative APT administration management is outdated and further development of PFT based, personalized APT administration/discontinuation management is desirable. This concept therefore presents a possible step forward in @entity0 care and provides a platform for further interventional trials whereby the impact of its application on clinical outcomes would be validated.

title: Development of a concept for a personalized approach in the perioperative antiplatelet therapy administration/discontinuation management based on multiple electrode aggregometry in XXXX undergoing coronary artery surgery.

answer: @entity0


abstract: @entity5 ( @entity7 ) was administered to 12 @entity0 for evaluation of clinical effects of @entity7 against secondary @entity2 complicated with @entity4 , and the following results were obtained. 1. The clinical effects were excellent in 1 and good in 8 out or 11 cases with efficacy rate of 81.8%. Out of 12 cases treated with @entity7 , 1 case was excluded from clinical evaluation because of prophylactic use. It is noted that all cases with @entity6 showed good response to @entity7 . 2. The serum levels of @entity7 were determined in 1 @entity0 with @entity1 . After intravenous drip infusion of 2 g in 200 ml of @entity3 solution, the serum concentrations were 67.2 micrograms/ml and 7.53 micrograms/ml at 14 hours and 24 hours (after hemodialysis), respectively. 3. No side effects attributed to @entity7 were observed. These results indicate that @entity7 is an effective and safe antibiotic for the treatment of severe @entity2 accompanying @entity4 .

title: [Effects of cefoxitin on @entity2 secondary to XXXX ].

answer: @entity4


abstract: @entity5 ( @entity7 ) was administered to 12 @entity0 for evaluation of clinical effects of @entity7 against secondary @entity2 complicated with @entity4 , and the following results were obtained. 1. The clinical effects were excellent in 1 and good in 8 out or 11 cases with efficacy rate of 81.8%. Out of 12 cases treated with @entity7 , 1 case was excluded from clinical evaluation because of prophylactic use. It is noted that all cases with @entity6 showed good response to @entity7 . 2. The serum levels of @entity7 were determined in 1 @entity0 with @entity1 . After intravenous drip infusion of 2 g in 200 ml of @entity3 solution, the serum concentrations were 67.2 micrograms/ml and 7.53 micrograms/ml at 14 hours and 24 hours (after hemodialysis), respectively. 3. No side effects attributed to @entity7 were observed. These results indicate that @entity7 is an effective and safe antibiotic for the treatment of severe @entity2 accompanying @entity4 .

title: [Effects of cefoxitin on XXXX secondary to @entity4 ].

answer: @entity2


abstract: UNASSIGNED: Research suggests gender differences exist in achieving undetectable viral load (UVL) among @entity0 living with @entity1 (PLHIV), and that psychosocial  health factors may play a role. The present study examined these factors among African-American PLHIV enrolled in the @entity3 study. @entity0 completed self-report surveys and gave biomarker data. Poisson regression with robust standard errors was implemented. @entity0 with moderate religious activity had 1.3 times the likelihood of UVL as @entity0 with low religious activity (p  <  0.10; N  =  199). @entity0 with 1-2 @entity2 diagnoses had 1.3 times the likelihood of UVL as @entity0 with none (p  <  0.05). @entity0 using 1-2 substances had 28  % lower likelihood of UVL than non-using @entity0 (N  =  122; p  <  0.10). Finally, @entity0 with frequent doctor- @entity0 communication had 35  % higher likelihood of UVL as @entity0 with less doctor- @entity0 communication (p  <  0.05). Results suggest that social support, substance use, and @entity2 function differently among @entity0 and @entity0 . Healthcare professionals should employ gender-specific interventions to address and improve @entity1 health outcomes.

title: Gender Differences in Psychosocial Factors Associated with XXXX Viral Suppression Among African-American Injection Drug Users.

answer: @entity1


abstract: BACKGROUND: Numerous therapeutic options have been tried in the management of @entity1 . AIMS AND OBJECTIVES: This prospective randomized study was planned to assess the efficacy of low potency triple combination (TC) cream (TC- @entity3 2%/ @entity2 0.05%/ @entity4 0.01%) versus @entity6 (GA) peels/ @entity5 (AA) 20% cream (GA/AA) combination in @entity1 . MATERIALS AND METHODS: Forty @entity0 with @entity1 were recruited into this study and randomized into two groups. Group A consisting 20 @entity0 received TC cream once a day for night time application for 3 months. Group B comprising of 20 @entity0 received GA/AA 20% cream combination for 3 months. The disease severity was monitored with digital photography, @entity1 area and severity index (MASI) score, which was calculated at baseline, 6 weeks and 12 weeks, and visual analog scale (VAS) score, which was calculated at baseline and 12 weeks. RESULTS: Of 40 @entity0 , 38 were completed the study. A significant reduction in MASI and VAS was recorded after 6 weeks and 12 weeks of treatment in both groups A and B (P = 0.001). However, there was no significant difference in the mean MASI scores between the two groups at baseline, 6 weeks and 12 weeks. Similarly, there was no difference in the mean VAS scores between the two groups at baseline and 12 weeks. Four @entity0 in group A and 3 in group B experienced adverse effects such as irritation, dryness, and photosensitivity. CONCLUSION: Both low potency TC cream and GA/AA 20% cream combination are effective in treating @entity1 among Indian @entity0 .

title: XXXX Peels/ @entity5 20% Cream Combination and Low Potency Triple Combination Lead to Similar Reduction in Melasma Severity in Ethnic Skin: Results of a Randomized Controlled Study.

answer: @entity6


abstract: BACKGROUND: Numerous therapeutic options have been tried in the management of @entity1 . AIMS AND OBJECTIVES: This prospective randomized study was planned to assess the efficacy of low potency triple combination (TC) cream (TC- @entity3 2%/ @entity2 0.05%/ @entity4 0.01%) versus @entity6 (GA) peels/ @entity5 (AA) 20% cream (GA/AA) combination in @entity1 . MATERIALS AND METHODS: Forty @entity0 with @entity1 were recruited into this study and randomized into two groups. Group A consisting 20 @entity0 received TC cream once a day for night time application for 3 months. Group B comprising of 20 @entity0 received GA/AA 20% cream combination for 3 months. The disease severity was monitored with digital photography, @entity1 area and severity index (MASI) score, which was calculated at baseline, 6 weeks and 12 weeks, and visual analog scale (VAS) score, which was calculated at baseline and 12 weeks. RESULTS: Of 40 @entity0 , 38 were completed the study. A significant reduction in MASI and VAS was recorded after 6 weeks and 12 weeks of treatment in both groups A and B (P = 0.001). However, there was no significant difference in the mean MASI scores between the two groups at baseline, 6 weeks and 12 weeks. Similarly, there was no difference in the mean VAS scores between the two groups at baseline and 12 weeks. Four @entity0 in group A and 3 in group B experienced adverse effects such as irritation, dryness, and photosensitivity. CONCLUSION: Both low potency TC cream and GA/AA 20% cream combination are effective in treating @entity1 among Indian @entity0 .

title: @entity6 Peels/ XXXX 20% Cream Combination and Low Potency Triple Combination Lead to Similar Reduction in Melasma Severity in Ethnic Skin: Results of a Randomized Controlled Study.

answer: @entity5


abstract: UNASSIGNED: @entity4 ( @entity4 ) is an extremely rare, benign @entity1 that originates from the neural crest tissue of the sympathetic nervous system. The majority of cases are detected incidentally, since the disease often lacks clear clinical manifestations or is asymptomatic. In addition, @entity4 is often misdiagnosed as being an @entity2 or @entity3 . The present study describes a 58-year-old female who visited the outpatient clinic of the Affiliated Hospital of Guangdong Medical College (Zhanjiang, Guangdong, China) with symptoms of face and lower extremity dropsy. Color Doppler ultrasonography revealed a solid @entity1 in the right kidney, and abdominal computed tomography identified an irregular, solid @entity1 measuring ~6*4.5*7 cm(3) and arising from the right adrenal gland, with a clear boundary. Magnetic resonance imaging was not performed. An initial diagnosis of @entity2 was established. The @entity0 was treated by laparoscopy in order to remove the @entity1 . However, following surgery, a pathological examination suggested that the @entity1 was a GN originating from the adrenal medulla. The formation of a correct diagnosis can be extremely challenging, as AGNs do not exhibit any specific clinical manifestations. Therefore, detection often depends entirely upon imaging studies, and the final diagnosis can be only by confirmed following a histopathological evaluation.

title: Laparoscopic resection of primary XXXX : A case report and review of the literature.

answer: @entity4


abstract: UNASSIGNED: Although @entity5 (Lib.) de Bary is a devastating necrotrophic fungal plant pathogen in agriculture, the virulence mechanisms utilized by @entity5 and the host defense mechanisms against this pathogen have not been fully understood. Here, we report that the @entity1 Mediator complex subunit @entity8 is a key component of basal resistance against @entity5 . Mutants of @entity8 are markedly more susceptible to @entity5 than mutants of thirteen other Mediator subunits, and @entity8 has a much stronger effect on @entity5 -induced transcriptome changes compared with med8, a mutation not altering susceptibility to @entity5 . Interestingly, @entity8 is also more susceptible to @entity5 than @entity7 -insensitive1-1 (coi1-1), which is the most susceptible mutant so far reported. Although the @entity3 (JA)/ @entity2 (ET) defense pathway marker gene PLANT DEFENSIN1.2 ( @entity4 ) cannot be induced in either @entity8 or coi1-1, basal transcript levels of @entity4 in @entity8 are significantly lower than in coi1-1. Furthermore, ET-induced suppression of JA-activated wound responses is compromised in @entity8 , suggesting a role for @entity8 in JA-ET crosstalk. Additionally, @entity8 is required for recruitment of RNA polymerase II to @entity4 and OCTADECANOID-RESPONSIVE @entity1 AP2/ERF59 (ORA59), two target genes of both JA/ET-mediated and the transcription factor @entity6 -activated defense pathways. Finally, @entity8 is physically associated with @entity6 in @entity0 and in planta, and @entity6 -activated transcription of @entity4 and ORA59 as well as resistance to @entity5 depends on @entity8 . Taken together, these results indicate that @entity8 regulates resistance to @entity5 by governing both JA/ET-mediated and @entity6 -activated defense signaling in @entity1 .

title: The @entity1 Mediator Complex Subunit16 Is a Key Component of Basal Resistance Against the Necrotrophic Fungal Pathogen XXXX .

answer: @entity5


abstract: UNASSIGNED: Although @entity5 (Lib.) de Bary is a devastating necrotrophic fungal plant pathogen in agriculture, the virulence mechanisms utilized by @entity5 and the host defense mechanisms against this pathogen have not been fully understood. Here, we report that the @entity1 Mediator complex subunit @entity8 is a key component of basal resistance against @entity5 . Mutants of @entity8 are markedly more susceptible to @entity5 than mutants of thirteen other Mediator subunits, and @entity8 has a much stronger effect on @entity5 -induced transcriptome changes compared with med8, a mutation not altering susceptibility to @entity5 . Interestingly, @entity8 is also more susceptible to @entity5 than @entity7 -insensitive1-1 (coi1-1), which is the most susceptible mutant so far reported. Although the @entity3 (JA)/ @entity2 (ET) defense pathway marker gene PLANT DEFENSIN1.2 ( @entity4 ) cannot be induced in either @entity8 or coi1-1, basal transcript levels of @entity4 in @entity8 are significantly lower than in coi1-1. Furthermore, ET-induced suppression of JA-activated wound responses is compromised in @entity8 , suggesting a role for @entity8 in JA-ET crosstalk. Additionally, @entity8 is required for recruitment of RNA polymerase II to @entity4 and OCTADECANOID-RESPONSIVE @entity1 AP2/ERF59 (ORA59), two target genes of both JA/ET-mediated and the transcription factor @entity6 -activated defense pathways. Finally, @entity8 is physically associated with @entity6 in @entity0 and in planta, and @entity6 -activated transcription of @entity4 and ORA59 as well as resistance to @entity5 depends on @entity8 . Taken together, these results indicate that @entity8 regulates resistance to @entity5 by governing both JA/ET-mediated and @entity6 -activated defense signaling in @entity1 .

title: The XXXX Mediator Complex Subunit16 Is a Key Component of Basal Resistance Against the Necrotrophic Fungal Pathogen @entity5 .

answer: @entity1


abstract: BACKGROUND: Research suggests that exclusive breastfeeding may have a stress-protective role in postpartum @entity2 ; however, less is known about the underlying mechanisms by which this protection may occur or whether the protective relationship holds for @entity0 who mix breast and bottle feeding. OBJECTIVES: To examine patterns of the stress response, @entity1 , and @entity2 among @entity0 predominantly breastfeeding or bottle feeding their @entity0 at 6 months postpartum. DESIGN: A part of a larger longitudinal study across 6 months postpartum investigating the psychoneuroimmunology (PNI) of postpartum @entity2 . SETTING: Prenatal clinics and community. @entity0 : One hundred nineteen postpartum @entity0 who met inclusion/exclusion criteria and followed up from the prenatal period to postpartum 6 months. METHODS: Data were collected during seven home visits occurring during the 3rd trimester (weeks 32-36) and on postpartum days 7 and 14, months 1, 2, 3, and 6. @entity0 completed stress and @entity2 surveys and provided blood for pro- ( @entity9 , @entity5 , @entity6 , @entity3 , @entity4 ) and anti-inflammatory ( @entity7 ) cytokines, and collected saliva for diurnal @entity8 . RESULTS: Self-report of predominant breastfeeding during 6 months postpartum ranged from 91.9% at day 7 to 70.6% at month 6 postpartum. There were no associations between the pattern of feeding and @entity2 . Biological differences, however, existed between the groups, with levels of salivary @entity8 at 8 AM and 8:30 AM at month 6 higher and levels of @entity5 at month 6 lower in @entity0 who primarily breastfed compared to those who primarily bottle fed their @entity0 after controlling for confounding variables. CONCLUSIONS: Breastfeeding was not related to postpartum @entity2 however differences in stress and inflammatory markers are apparent at month 6 postpartum.

title: The association between breastfeeding, the stress response, @entity1 , and postpartum XXXX during the postpartum period: Prospective cohort study.

answer: @entity2


abstract: BACKGROUND: Research suggests that exclusive breastfeeding may have a stress-protective role in postpartum @entity2 ; however, less is known about the underlying mechanisms by which this protection may occur or whether the protective relationship holds for @entity0 who mix breast and bottle feeding. OBJECTIVES: To examine patterns of the stress response, @entity1 , and @entity2 among @entity0 predominantly breastfeeding or bottle feeding their @entity0 at 6 months postpartum. DESIGN: A part of a larger longitudinal study across 6 months postpartum investigating the psychoneuroimmunology (PNI) of postpartum @entity2 . SETTING: Prenatal clinics and community. @entity0 : One hundred nineteen postpartum @entity0 who met inclusion/exclusion criteria and followed up from the prenatal period to postpartum 6 months. METHODS: Data were collected during seven home visits occurring during the 3rd trimester (weeks 32-36) and on postpartum days 7 and 14, months 1, 2, 3, and 6. @entity0 completed stress and @entity2 surveys and provided blood for pro- ( @entity9 , @entity5 , @entity6 , @entity3 , @entity4 ) and anti-inflammatory ( @entity7 ) cytokines, and collected saliva for diurnal @entity8 . RESULTS: Self-report of predominant breastfeeding during 6 months postpartum ranged from 91.9% at day 7 to 70.6% at month 6 postpartum. There were no associations between the pattern of feeding and @entity2 . Biological differences, however, existed between the groups, with levels of salivary @entity8 at 8 AM and 8:30 AM at month 6 higher and levels of @entity5 at month 6 lower in @entity0 who primarily breastfed compared to those who primarily bottle fed their @entity0 after controlling for confounding variables. CONCLUSIONS: Breastfeeding was not related to postpartum @entity2 however differences in stress and inflammatory markers are apparent at month 6 postpartum.

title: The association between breastfeeding, the stress response, XXXX , and postpartum @entity2 during the postpartum period: Prospective cohort study.

answer: @entity1


abstract: The inadequacy of the standard bacteriological method in the study of expectorations is unanimously accepted. Oropharyngeal contamination of specimens largely explains why this examination is a poor index of the causative organisms in bacterial @entity4 . In a mixed clinical situation with few or non-specific signs of @entity5 and of variable severity, the physician should answer two questions: 1) Is it a @entity5 ? 2) What is the causative organism? and their corollary: 1) Should one prescribe an antibiotic? 2) Which one? Only culture of blood or pleural fluid allow an accurate reply to these questions in about 50% of cases and they are the indispensable investigations of reference. Initial efforts undertaken to improve the standard examination of expectorations never overcome the stumbling block of oro-pharyngeal contaminations. The bacterial count of expectorated bacteria, a non traumatic method, represents some real progress. In 50% of cases it enables a predominant pathogen to be identified before any antibiotics are given. Bronchoscopy diminishes contamination, allows direct sampling and the inspection and biopsying of @entity6 and aids drainage in @entity1 . Trans-tracheal puncture avoids oropharyngeal contamination in the majority of cases and appears to provide reliable results much more often. A pragmatic approach is recommended according to the clinical picture. Bronchial and limited @entity3 which are well tolerated, heal without exception on blind antibiotic therapy. In suppurating infections ( @entity7 , cavitating @entity0 ), the yield and the reliability of the examinations are increased. Serious @entity5 , by their extent or by their site, justify a more aggressive diagnostic and therapeutic attitude. It should be stressed, however, that @entity2 caused by inadequate antibiotic therapy remains the exception when one or two successive courses of antibiotics have been prescribed for the pathogens presumed responsible according to the clinical picture or found after one or more bacterial examinations.

title: [Bacteriology of bronchial secretions. Proposals for a practical XXXX ].

answer: @entity4


abstract: BACKGROUND: The " @entity4 trunk" (ET) technique traditionally has been performed to treat complex aortic diseases involving the aortic arch and the descending aorta. Despite the fact that, in recent years, the "frozen @entity4 trunk" (FET) technique has been used increasingly for such pathologies, discussion is still ongoing in the surgical community regarding which of the 2 techniques is better. We compared our results using the classic ET versus the FET technique. METHODS: From August 2001 to March 2013, a total of 277 @entity0 underwent total aortic arch replacement and either ET (group A) or FET (group B) implantation. In group A, 97 @entity0 (59 @entity0 ; age 59.7    12.7 years; 44.3% with @entity2 ; 55.6% with dissection [48.45% acute]) underwent an ET procedure; 21.64% were reoperations. In group B, 180 @entity0 underwent an FET procedure (126 @entity0 ; age 59.8    13.2 years; 34.4% with @entity2 ; 63.3% with dissection [35% acute]); 30% were reoperations. RESULTS: In group A, in-hospital mortality was 24.7%; @entity1 rate was 12.4%. During follow-up, 27.8% underwent a second-stage procedure. In group B, in-hospital mortality was 12.2%; @entity1  rate was 13.3%. During follow-up, 27.7% @entity0 underwent further interventions in the downstream aorta. CONCLUSIONS: In selected @entity0 with combined aortic arch and descending @entity3 limited to the proximal descending aorta, the FET approach potentially allows for single-stage therapy, whereas a second-stage operation is inevitable with the classic ET approach. Moreover, owing to the availability of prefabricated, easy-to-use, FET, hybrid prostheses that result in significantly better outcomes in @entity0 who have acute aortic dissection, type A, and if necessary, and provide an ideal "landing zone" for future endovascular completion, the classic ET procedure is "freezing," in the sense that it is being replaced by the FET approach.

title: The XXXX trunk is freezing: The Hannover experience.

answer: @entity4


abstract: PURPOSE: This study was designed to seek associations between positron emission tomography/computed tomography (PET/CT) parameters, contrast enhanced neck computed tomography (CECT) and pathological findings, and to determine the potential prognostic value of PET/CT and CECT parameters in @entity5 ( @entity5 ). MATERIALS AND METHOD: 36 @entity5 @entity0 underwent staging PET/CT and 30/36 of @entity0 had CECT. PET/CT parameters were measured for the @entity2 and the hottest involved node, including maximum, mean, and peak standardized uptake values (SUV max, SUV mean, and SUV peak), metabolic @entity2 volume (MTV), total lesion glycolysis (TLG), @entity3 ( @entity3 ), and normalized @entity3 (N @entity3 ). Qualitative assessment of PET/CT and CECT were also performed. Pathological outcomes included: perineural invasion, @entity1 , nodal extracapsular spread, grade, pathologic T and N stages. Multivariable logistic regression models were fit for each parameter and outcome adjusting for potentially confounding variables. Multivariable Cox proportional hazards models were used for progression free survival (PFS), locoregional recurrence free survival (LRFS), @entity4 ( @entity4 ) and distant @entity1 free survival (DMFS). RESULTS: In multivariable analysis, @entity0 with high (>=  median) @entity2 SUV max (OR 6.3), SUV mean (OR 6.3), MTV (OR 19.0), TLG (OR 19.0), @entity3 (OR 11.7) and N @entity3 (OR 19.0) had high pathological T-stage (T3/T4) (p<0.05). Ring/heterogeneous pattern on CECT qualitative assessment was associated with worse DMFS and @entity4 . CONCLUSION: High PET/CT parameters were associated with pathologically advanced T stage (T3/T4). Qualitative assessment of CECT has prognostic value. PET/CT parameters did not predict clinical outcome.

title: 18F-FDG-PET/CT parameters as imaging biomarkers in XXXX , is visual analysis of PET and contrast enhanced CT better than the numbers?

answer: @entity5


abstract: Bile duct ligation in the @entity0 leads to a rapid increase in hepatic and serum alkaline phosphatase activity. Within 12 hr after bile duct ligation, hepatic alkaline phosphatase has increased 7-fold and serum alkaline phosphatase activity 2(1/2)-fold. The elevation in the serum activity is completely due to an increase in an isozyme that appears to originate in the liver. This serum isozyme and liver phosphatase, both partially purified by @entity5 -cellulose column chromatography, have identical Michaelis constants, pH optima, and rates of heat denaturation. These isozymes migrate identically when subjected to electrophoresis on @entity3 gel, and their migration rates are equally slowed after neuraminidase digestion. The data suggest that the rise in hepatic alkaline phosphatase activity is dependent on de novo protein synthesis. @entity2 , in a dose that inhibited incorporation of @entity1 - @entity4 into protein by 68%, inhibited the rise in liver phosphatase by 98% and that in serum by 80%. The rise in liver phosphatase activity could not be accounted for by simple retention of alkaline phosphatase that would normally appear in bile. The rise in liver activity after bile duct ligation was 240 times greater than the amount of phosphatase that normally appears in bile over a similar period of time. @entity2 had no effect on the bile duct ligation-induced changes in the serum and liver glutamic pyruvic transaminase.

title: Induction of XXXX liver alkaline phosphatase: the mechanism of the serum elevation in bile duct obstruction.

answer: @entity0


abstract: BACKGROUND: @entity7 ( @entity7 ) and @entity7 (definite @entity7 ) have similar cerebral angiographic features, but whether these @entity1 have similar etiology or genetic background remains unclear. Recently, we have reported that the recently identified @entity7 susceptibility gene variant @entity8 @entity10 ( @entity9 ) was associated with @entity3 intracranial major @entity6 /occlusion. The present study investigated the occurrence of @entity8 @entity10 in @entity0 with nonatherosclerotic quasi- @entity7 . METHODS: This study was a 2-hospital-based case-control study conducted at the Department of Neurosurgery, The University of Tokyo Hospital and Kanto Neurosurgical Hospital. A total of 87 Japanese @entity0 who agreed to participate in this study were enrolled among both new and revisiting outpatients from October 2011 to December 2013 as follows: 78 @entity0 with definite @entity7 and 9 @entity0 with nonatherosclerotic quasi- @entity7 . RESULTS: The 9 @entity0 with nonatherosclerotic quasi- @entity7 included 3 @entity0 with previous irradiation, 2 with @entity4 , 1 with @entity5 , 1 with @entity2 , 1 with Beh  et disease, and 1 with idiopathic @entity2 . The 78 @entity0 with definite @entity7 included 66 @entity0 (84.6%) with the @entity10 variant (64 heterozygotes and 2 homozygous). In contrast, no @entity0 with nonatherosclerotic quasi- @entity7 had the variant. CONCLUSIONS: Nonatherosclerotic quasi- @entity7 did not have @entity8 @entity10 variant. @entity7 and @entity1 might be classified by genetic analysis of the @entity8 @entity10 genotype. Further larger studies are required to confirm the present findings.

title: Genetic Analysis of XXXX @entity10 Variant in Nonatherosclerotic Quasi-Moyamoya Disease.

answer: @entity8


abstract: BACKGROUND: @entity7 ( @entity7 ) and @entity7 (definite @entity7 ) have similar cerebral angiographic features, but whether these @entity1 have similar etiology or genetic background remains unclear. Recently, we have reported that the recently identified @entity7 susceptibility gene variant @entity8 @entity10 ( @entity9 ) was associated with @entity3 intracranial major @entity6 /occlusion. The present study investigated the occurrence of @entity8 @entity10 in @entity0 with nonatherosclerotic quasi- @entity7 . METHODS: This study was a 2-hospital-based case-control study conducted at the Department of Neurosurgery, The University of Tokyo Hospital and Kanto Neurosurgical Hospital. A total of 87 Japanese @entity0 who agreed to participate in this study were enrolled among both new and revisiting outpatients from October 2011 to December 2013 as follows: 78 @entity0 with definite @entity7 and 9 @entity0 with nonatherosclerotic quasi- @entity7 . RESULTS: The 9 @entity0 with nonatherosclerotic quasi- @entity7 included 3 @entity0 with previous irradiation, 2 with @entity4 , 1 with @entity5 , 1 with @entity2 , 1 with Beh  et disease, and 1 with idiopathic @entity2 . The 78 @entity0 with definite @entity7 included 66 @entity0 (84.6%) with the @entity10 variant (64 heterozygotes and 2 homozygous). In contrast, no @entity0 with nonatherosclerotic quasi- @entity7 had the variant. CONCLUSIONS: Nonatherosclerotic quasi- @entity7 did not have @entity8 @entity10 variant. @entity7 and @entity1 might be classified by genetic analysis of the @entity8 @entity10 genotype. Further larger studies are required to confirm the present findings.

title: Genetic Analysis of @entity8 XXXX Variant in Nonatherosclerotic Quasi-Moyamoya Disease.

answer: @entity10


abstract: INTRODUCTION: @entity7 ( @entity7 ) is the most common variant of @entity3 . Although @entity7 often has an indolent course, @entity0 can progress to, or present with, advanced stage (stage IIB-IVB) @entity7 or with the @entity6 ( @entity8 ). @entity0 AND METHODS: We prospectively evaluated multiple prognostic variables, including demographics, age, TNMB (blood) stage, histologic features, @entity4 dehydrogenase (LDH), white blood cell counts, and response to treatment, in 168 @entity0 with @entity1 and @entity8 from 2007 to June 2014. Kaplan-Meier estimates were used to determine the median @entity5 ( @entity5 ) and @entity2 ( @entity2 ). A Cox proportional hazards regression model was used to assess the prognostic factors with univariate and multivariate analyses. RESULTS: We analyzed 140 @entity0 with @entity7 and 28 with @entity8 , whose median survival was 2.47 years. A total of 79 @entity0 (47%) died of any cause. On univariate analysis, age, lymph node stage, and serum LDH level were significant for prognosis. On multivariate analysis, skin and node stage, age, large cell transformation, and LDH level were significantly associated with worse @entity5 . Only N stage and LDH were significant for @entity2 . @entity0 who had received biologic response modifiers and histone deacetylase inhibitors first had better survival (2.5 years) than the @entity0 initially treated with multiagent chemotherapy (9 months). CONCLUSION: We found that only a few factors can predict @entity5 and @entity2 for @entity0 with advanced @entity7 / @entity8 . Also, nonchemotherapy options should be preferred for front-line therapy to improve survival, outcomes, and side effects, including immunosuppression.

title: XXXX and S  zary syndrome: survival and response to treatment.

answer: @entity1


abstract: BACKGROUND: @entity9 ( @entity9 ) is a very distressing symptom and remains one of the most frustrating and potentially disabling symptoms in @entity0 with @entity4 ( @entity4 ). Its etiopathogenesis remains unclear and complex. The aim of this study was to investigate the possible role of @entity8 ( @entity8 ) in @entity9 , and correlate its level with the severity of itching in @entity4 @entity0 . @entity0 AND METHODS: This study was carried out on 60 @entity0 on maintenance hemodialysis (HD), 30 @entity0 with @entity9 and 30 @entity0 without @entity9 , and 30 apparently healthy age- and sex-matched subjects as controls. @entity11 intensity was scored as mild, moderate, and severe using five-dimensional @entity11 scale. Some relevant clinical parameters (age, sex, xerosis, presence of @entity1 , duration of dialysis, complete medical history, and history of pruritic @entity3 ) and laboratory findings including @entity6 , @entity7 , @entity5 , @entity10 , parathyroid hormone, and serum levels of @entity8 were evaluated. RESULTS: In our study, we found a statistically significant difference in @entity8 level between @entity0 and controls. However, there was no statistically significant difference in @entity8 levels between cases with @entity2 and cases without @entity2 . Also, there was a statistically significant relation between @entity8 level and duration of the disease. CONCLUSION: Further studies are needed to understand the contribution of @entity8 and possibly other cytokines in the pathogenesis of this distressing symptom in @entity4 .

title: Role of XXXX in @entity9 Among Attendants of AL-Zahraa Hospital Dialysis Unit.

answer: @entity8


abstract: BACKGROUND: @entity9 ( @entity9 ) is a very distressing symptom and remains one of the most frustrating and potentially disabling symptoms in @entity0 with @entity4 ( @entity4 ). Its etiopathogenesis remains unclear and complex. The aim of this study was to investigate the possible role of @entity8 ( @entity8 ) in @entity9 , and correlate its level with the severity of itching in @entity4 @entity0 . @entity0 AND METHODS: This study was carried out on 60 @entity0 on maintenance hemodialysis (HD), 30 @entity0 with @entity9 and 30 @entity0 without @entity9 , and 30 apparently healthy age- and sex-matched subjects as controls. @entity11 intensity was scored as mild, moderate, and severe using five-dimensional @entity11 scale. Some relevant clinical parameters (age, sex, xerosis, presence of @entity1 , duration of dialysis, complete medical history, and history of pruritic @entity3 ) and laboratory findings including @entity6 , @entity7 , @entity5 , @entity10 , parathyroid hormone, and serum levels of @entity8 were evaluated. RESULTS: In our study, we found a statistically significant difference in @entity8 level between @entity0 and controls. However, there was no statistically significant difference in @entity8 levels between cases with @entity2 and cases without @entity2 . Also, there was a statistically significant relation between @entity8 level and duration of the disease. CONCLUSION: Further studies are needed to understand the contribution of @entity8 and possibly other cytokines in the pathogenesis of this distressing symptom in @entity4 .

title: Role of @entity8 in XXXX Among Attendants of AL-Zahraa Hospital Dialysis Unit.

answer: @entity9


abstract: UNASSIGNED: Aberrant increase in protein kinase B ( @entity3 ) phosphorylation (pAKT), due to a gain-of-function mutation of @entity5 -3-kinase (PI3K) or loss-of-function mutation or deletion of phosphatase and tensin homolog ( @entity4 ), is a common alteration in @entity1 and associated with poor prognosis. Cytosolic phospholipase A2a ( @entity6 ) is a lipid modifying enzyme by catalyzing the hydrolysis of @entity2 from membrane phospholipid. The released @entity2 and its metabolites contribute to survival and proliferation of @entity1 cells. In this mini-review, we summarize the relationship between pAKT and @entity6 in @entity1 cells. There was a concordant increase in pAKT and @entity6 levels in prostate tissue of prostate epithelial-specific @entity4 -knockout @entity0 compared to @entity4 -wild type @entity0 . Restoration of @entity4 expression or inhibition of PI3K action decreased @entity6 expression in @entity4 -mutated or deleted @entity1 cells. An increase in @entity3 phosphorylation elevated, whereas inhibition of @entity3 phosphorylation diminished, @entity6 protein levels. pAKT had no influence on @entity6 a expression at mRNA levels but stabilized @entity6 at protein levels by protecting it from degradation. Conversely, an induction of @entity6 expression led to an increase in pAKT levels in @entity4 -mutated or deleted @entity1 cells, while silencing of @entity6 expression or pharmacological blocking @entity6 a action decreased pAKT levels. The diminishment of pAKT by either genetic silencing or pharmacological blocking of @entity6 was mitigated by the addition of @entity2 . The stimulatory effect of @entity2 on pAKT levels was lessened by inhibiting the production of @entity2 metabolites. These studies have revealed a link between oncogenic pathway and lipid metabolism and provided potential molecular targets for treating @entity1 .

title: @entity3 and cytosolic phospholipase A2a form a positive loop in XXXX cells.

answer: @entity1


abstract: UNASSIGNED: Aberrant increase in protein kinase B ( @entity3 ) phosphorylation (pAKT), due to a gain-of-function mutation of @entity5 -3-kinase (PI3K) or loss-of-function mutation or deletion of phosphatase and tensin homolog ( @entity4 ), is a common alteration in @entity1 and associated with poor prognosis. Cytosolic phospholipase A2a ( @entity6 ) is a lipid modifying enzyme by catalyzing the hydrolysis of @entity2 from membrane phospholipid. The released @entity2 and its metabolites contribute to survival and proliferation of @entity1 cells. In this mini-review, we summarize the relationship between pAKT and @entity6 in @entity1 cells. There was a concordant increase in pAKT and @entity6 levels in prostate tissue of prostate epithelial-specific @entity4 -knockout @entity0 compared to @entity4 -wild type @entity0 . Restoration of @entity4 expression or inhibition of PI3K action decreased @entity6 expression in @entity4 -mutated or deleted @entity1 cells. An increase in @entity3 phosphorylation elevated, whereas inhibition of @entity3 phosphorylation diminished, @entity6 protein levels. pAKT had no influence on @entity6 a expression at mRNA levels but stabilized @entity6 at protein levels by protecting it from degradation. Conversely, an induction of @entity6 expression led to an increase in pAKT levels in @entity4 -mutated or deleted @entity1 cells, while silencing of @entity6 expression or pharmacological blocking @entity6 a action decreased pAKT levels. The diminishment of pAKT by either genetic silencing or pharmacological blocking of @entity6 was mitigated by the addition of @entity2 . The stimulatory effect of @entity2 on pAKT levels was lessened by inhibiting the production of @entity2 metabolites. These studies have revealed a link between oncogenic pathway and lipid metabolism and provided potential molecular targets for treating @entity1 .

title: XXXX and cytosolic phospholipase A2a form a positive loop in @entity1 cells.

answer: @entity3


abstract: UNASSIGNED: Accurate identification of factors associated with progression of @entity2 remains a challenge. In particular, it is unclear which statistical methods are most suitable to separate the effects of putative prognostic factors on @entity1 progression vs @entity1 -specific and other cause mortality. To address these challenges, we analyzed 10 year follow-up data for @entity0 who underwent curative surgery for @entity2 in 1985-2000. Separate analyses were performed in two French @entity1 registries. Results of three multivariable models were compared: Cox model with recurrence as a time-dependent variable, and two multi-state models, which separated prognostic factor effects on recurrence vs @entity3 , with or without recurrence. Conventional multi-state model analyzed all-cause mortality while new relative survival multi-state model focused on @entity1 -specific mortality. Among the 2517 and 2677 @entity0 in the two registries, about 50% died without a recurrence, and 28% had a recurrence, of whom almost 90% died. In both multi-state models @entity0 had significantly increased risk of @entity1 recurrence in both registries (HR=0.79; 95% CI: 0.68-0.92 and HR=0.83; 95% CI: 0.71-0.96). However, the two multi-state models identified different prognostic factors for mortality without recurrence. In contrast to the conventional model, in the relative survival analyses gender had no independent association with @entity1 -specific mortality whereas @entity0 diagnosed with @entity1 had significantly higher risks in both registries (HR=1.67; 95% CI: 1.27-2.22 and HR=2.38; 95% CI: 1.29-3.27). In conclusion, relative survival multi-state model revealed that different factors may be associated with @entity1 recurrence vs @entity1 -specific mortality either after or without a recurrence.

title: Multi-state relative survival modelling of XXXX progression and mortality.

answer: @entity2


abstract: OBJECTIVE: To examine the relationship between postpartum @entity1 and postpartum @entity2 and describe the characteristics and demographics of the samples. DATA SOURCES: Electronic databases Medline, PubMed, Cochrane, EPOC, CINAHL, ProQuest, and Psych INFO. In addition, hand searches of bibliographies supplemented the electronic search. STUDY SELECTION: English language primary studies on the relationship between postpartum @entity1 and postpartum @entity2 were included. Thirteen observational studies met the inclusion criteria. DATA EXTRACTION: Data that specified the relationship between @entity1 and postpartum @entity2 were extracted from the studies. The data were organized per author, year, @entity0 , setting, country, demographics, design, sample size, outcomes, evidence, and effect size. DATA SYNTHESIS: The effect size indicating the relationship between @entity1 and postpartum @entity2 across the studies ranged between 0.4 and 1.7. There was evidence of a strong relationship between @entity1 and postpartum @entity2 ; however, the @entity0 in the 13 studies were predominantly educated, middle class, older than age 30 years, and White. Likewise, the definition and measurement of postpartum sleep varied across the studies, which increased the possibility of bias. CONCLUSIONS: Further research within the postpartum period involving underserved, younger @entity0 and samples with more diversity in race and ethnicity are needed.

title: A Systematic Review of the Relationship Between Postpartum Sleep Disturbance and Postpartum XXXX .

answer: @entity2


abstract: BACKGROUND: Brain scans are essential to exclude @entity4 in @entity0 with suspected acute @entity2 before treatment with alteplase. However, @entity0 with early ischaemic signs could be at increased risk of @entity4 after alteplase treatment, and little information is available about whether pre-existing structural signs, which are common in older @entity0 , affect response to alteplase. We aimed to investigate the association between imaging signs on brain CT and outcomes after alteplase. METHODS: IST-3 was a multicentre, randomised controlled trial of intravenous alteplase (0  9 mg/kg) versus control within 6 h of acute @entity2 . The primary outcome was independence at 6 months (defined as an Oxford Handicap Scale [OHS] score of 0-2). 3035 @entity0 were enrolled to IST-3 and underwent prerandomisation brain CT. Experts who were unaware of the random allocation assessed scans for early signs of ischaemia (tissue hypoattenuation, @entity6 extent, @entity1 , and hyperattenuated artery) and pre-existing signs ( @entity6 , @entity7 , and @entity3 ). In this prespecified analysis, we assessed interactions between these imaging signs, symptomatic @entity5 (a secondary outcome in IST-3) and independence at 6 months, and alteplase, adjusting for age, National Institutes of Health @entity2 Scale (NIHSS) score, and time to randomisation. This trial is registered at ISRCTN.com, number ISRCTN25765518. FINDINGS: 3017 @entity0 were assessed in this analysis, of whom 1507 were allocated alteplase and 1510 were assigned control. A reduction in independence was predicted by tissue hypoattenuation (odds ratio 0  66, 95% CI 0  55-0  81), large lesion (0  51, 0  38-0  68), @entity1 (0  59, 0  46-0  75), hyperattenuated artery (0  59, 0  47-0  75), @entity3 (0  74, 0  59-0  94), and @entity7 (0  72, 0  59-0  87). Symptomatic @entity5 was predicted by @entity6 (odds ratio 1  72, 95% CI 1  18-2  51), tissue hypoattenuation (1  54, 1  04-2  27), and hyperattenuated artery (1  54, 1  03-2  29). Some combinations of signs increased the absolute risk of symptomatic @entity5 (eg, both @entity6 and hyperattenuated artery, excess with alteplase 13  8%, 95% CI 6  9-20  7; both signs absent, excess 3  2%, 1  4-5  1). However, no imaging findings-individually or combined-modified the effect of alteplase on independence or symptomatic @entity5 . INTERPRETATION: Some early ischaemic and pre-existing signs were associated with reduced independence at 6 months and increased symptomatic @entity5 . Although no interaction was noted between brain imaging signs and effects of alteplase on these outcomes, some combinations of signs increased some absolute risks. Pre-existing signs should be considered, in addition to early ischaemic signs, during the assessment of @entity0 with acute @entity2 . FUNDING: UK Medical Research Council, Health Foundation UK, @entity2 Association UK, Chest @entity2 Scotland, Scottish Funding Council SINAPSE Collaboration, and multiple governmental and philanthropic national funders.

title: Association between brain imaging signs, early and late outcomes, and response to intravenous alteplase after acute XXXX in the third International @entity2 Trial (IST-3): secondary analysis of a randomised controlled trial.

answer: @entity2


abstract: BACKGROUND: Brain scans are essential to exclude @entity4 in @entity0 with suspected acute @entity2 before treatment with alteplase. However, @entity0 with early ischaemic signs could be at increased risk of @entity4 after alteplase treatment, and little information is available about whether pre-existing structural signs, which are common in older @entity0 , affect response to alteplase. We aimed to investigate the association between imaging signs on brain CT and outcomes after alteplase. METHODS: IST-3 was a multicentre, randomised controlled trial of intravenous alteplase (0  9 mg/kg) versus control within 6 h of acute @entity2 . The primary outcome was independence at 6 months (defined as an Oxford Handicap Scale [OHS] score of 0-2). 3035 @entity0 were enrolled to IST-3 and underwent prerandomisation brain CT. Experts who were unaware of the random allocation assessed scans for early signs of ischaemia (tissue hypoattenuation, @entity6 extent, @entity1 , and hyperattenuated artery) and pre-existing signs ( @entity6 , @entity7 , and @entity3 ). In this prespecified analysis, we assessed interactions between these imaging signs, symptomatic @entity5 (a secondary outcome in IST-3) and independence at 6 months, and alteplase, adjusting for age, National Institutes of Health @entity2 Scale (NIHSS) score, and time to randomisation. This trial is registered at ISRCTN.com, number ISRCTN25765518. FINDINGS: 3017 @entity0 were assessed in this analysis, of whom 1507 were allocated alteplase and 1510 were assigned control. A reduction in independence was predicted by tissue hypoattenuation (odds ratio 0  66, 95% CI 0  55-0  81), large lesion (0  51, 0  38-0  68), @entity1 (0  59, 0  46-0  75), hyperattenuated artery (0  59, 0  47-0  75), @entity3 (0  74, 0  59-0  94), and @entity7 (0  72, 0  59-0  87). Symptomatic @entity5 was predicted by @entity6 (odds ratio 1  72, 95% CI 1  18-2  51), tissue hypoattenuation (1  54, 1  04-2  27), and hyperattenuated artery (1  54, 1  03-2  29). Some combinations of signs increased the absolute risk of symptomatic @entity5 (eg, both @entity6 and hyperattenuated artery, excess with alteplase 13  8%, 95% CI 6  9-20  7; both signs absent, excess 3  2%, 1  4-5  1). However, no imaging findings-individually or combined-modified the effect of alteplase on independence or symptomatic @entity5 . INTERPRETATION: Some early ischaemic and pre-existing signs were associated with reduced independence at 6 months and increased symptomatic @entity5 . Although no interaction was noted between brain imaging signs and effects of alteplase on these outcomes, some combinations of signs increased some absolute risks. Pre-existing signs should be considered, in addition to early ischaemic signs, during the assessment of @entity0 with acute @entity2 . FUNDING: UK Medical Research Council, Health Foundation UK, @entity2 Association UK, Chest @entity2 Scotland, Scottish Funding Council SINAPSE Collaboration, and multiple governmental and philanthropic national funders.

title: Association between brain imaging signs, early and late outcomes, and response to intravenous alteplase after acute @entity2 in the third International XXXX Trial (IST-3): secondary analysis of a randomised controlled trial.

answer: @entity2